SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022.
The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Monday, November 14, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13732765. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1569474&tp_key=bb26315c9c. Following the live webcast, an archived version of the call will be available on the website.
Monday November 14 @ 4:30 pm ET | |
Domestic: | 1-877-407-0792 |
International: | 1-201-689-8263 |
Conference ID: | 13732765 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1569474&tp_key=bb26315c9c |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.
For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com
Company to also highlight advancements in denials and underpayments management and speak to the measurable…
Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…
Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…
Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…